

# Ravi P Shah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5859814/publications.pdf>

Version: 2024-02-01

17  
papers

537  
citations

840585

11  
h-index

887953

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

473  
citing authors

#	ARTICLE	IF	CITATIONS
1	A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 69, 148-173.	1.4	166
2	Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 87, 191-217.	1.4	77
3	Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MSn, on-line H/D exchange and LC-NMR. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 1037-1046.	1.4	55
4	Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 613-622.	0.7	47
5	LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 52, 345-354.	1.4	35
6	Identification and characterization of a photolytic degradation product of telmisartan using LC-MS/TOF, LC-MSn, LC-NMR and on-line H/D exchange mass studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 53, 755-761.	1.4	24
7	Stress degradation studies on lornoxicam using LC, LC-MS/TOF and LC-MSn. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 538-545.	1.4	24
8	LC-MS/TOF, LC-MSn, on-line H/D exchange and LC-NMR studies on rosuvastatin degradation and in silico determination of toxicity of its degradation products: a comprehensive approach during drug development. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 3215-3231.	1.9	24
9	Strategy for identification and characterization of small quantities of drug degradation products using LC and LC-MS: Application to valsartan, a model drug. <i>Drug Testing and Analysis</i> , 2010, 2, 82-90.	1.6	23
10	Amalgamation of stress degradation and metabolite profiling in rat urine and feces for characterization of oxidative metabolites of flibanserin using UHPLC-Q-TOF-MS/MS, H/D exchange and NMR technique. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1139, 121993.	1.2	18
11	Practical and Economical Implementation of Online H/D Exchange in LC-MS. <i>Analytical Chemistry</i> , 2013, 85, 10904-10912.	3.2	14
12	A mechanistic explanation on degradation behavior of flibanserin for identification and characterization of its potential degradants using LC-DAD/ESI/APCI-Q-TOF-MS/MS. <i>Microchemical Journal</i> , 2021, 167, 106281.	2.3	11
13	LC and LC-HRMS studies on stability behavior of molnupiravir an anti-COVID 19 drug. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2021, 44, 750-759.	0.5	9
14	Exploring unexplored biomarkers of oxidative distress and their use. <i>Advances in Redox Research</i> , 2021, 3, 100020.	0.9	4
15	A systematic UHPLC-Q-TOF-MS/MS based analytical approach for characterization of flibanserin metabolites and establishment of biotransformation pathway. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1185, 123011.	1.2	2
16	LC-HRMS studies on ruxolitinib degradation: a comprehensive approach during drug development. <i>Analytical Methods</i> , 2022, 14, 480-490.	1.3	2
17	Synthetic pharmaceutical peptides characterization by chromatography principles and method development. <i>Journal of Separation Science</i> , 2022, 45, 2200-2216.	1.3	2